Cancer immunotherapy: a paradigm shift for prostate cancer treatment
Authors:
- Dev KaranDKDev Karan
- Jeffrey M. HolzbeierleinJHJeffrey M. Holzbeierlein
- Peter Van VeldhuizenPVPeter Van Veldhuizen
- J. Brantley ThrasherJTJ. Brantley Thrasher
- 29 May 2012
- journal article
- review article
- Published by Springer Nature in Nature Reviews Urology
- Vol. 9 (7) , 376-385
Abstract
Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by deleterious side effects. Immunotherapy represents a valuable alternative to conventional treatments by inducing tumour-specific immune responses that control the growth of cancer cells. Sipuleucel-T is approved by the FDA as an immunotherapeutic agent for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC). Although this approval has raised cost-versus-benefit issues, it has provided proof of concept for the therapeutic potential of active immunotherapy approaches for metastatic CRPC. Numerous clinical studies have demonstrated clinical benefit using immunotherapy compared to traditional chemotherapy and several active immunotherapy approaches (at various developmental stages)have demonstrated the potential to change the face of prostate cancer treatment.Keywords
This publication has 110 references indexed in Scilit:
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- The PCa Tumor MicroenvironmentCancer Microenvironment, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysisThe Prostate, 2009
- Prostate stem cell antigen: A prospective therapeutic and diagnostic targetCancer Letters, 2009
- Inflammation and cancerNature, 2002
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002